LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing the precision oncology landscape with its lead program, LB-100, a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation while reducing treatment-related side effects. The company aims to improve the therapeutic index of existing cancer modalities, addressing a key challenge in oncology: maximizing treatment impact while minimizing risks to healthy tissue.
LB-100 is a first-in-class PP2A inhibitor that has shown tolerability in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. The compound is part of a pioneering effort in a new field of cancer biology called activation lethality, covered by a comprehensive patent portfolio.
Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer. These trials aim to validate LB-100's ability to boost the effectiveness of standard treatments. The company’s focus on precision oncology represents a shift toward more targeted, less toxic cancer therapies.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company dedicated to developing and commercializing cancer therapies. The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT.
